Business
AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022
Expanded characterization of CD3-binding antibodies includes identification of antibodies that bind regions of CD3 that are distinct from commonly used
About this update from Abcellera Biologics Inc.
[{"type":"text","content":"\n\nExpanded characterization of CD3-binding antibodies includes identification of antibodies that bind regions of CD3 that are distinct from commonly used molecules\n\n\nRobust proof-of-concept study demonstrates T-cell engagers that potently eliminate cancer cells with minimal cytokine release\n\n\n VANCOUVER, British Columbia--(BUSINESS WIRE)--\nAbCellera (Nasdaq: ABCL) today announced the release of new data on its T-cell engager (TCE) platform at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022. AbCellera’s poster presentation describes the expansion, further characterization, and validation of a diverse panel of CD3-binding antibodies that can be used to develop T-cell engagers for cancer treatments.\n\n“The robust data package we are presenting at SITC demonstrates that our panel includes antibodies that are distinct from molecules commonly used for CD3 T-cell engager development,” said Bo Barnhart, Ph.D., VP, Translational Research at AbCellera. “By combining this panel with the OrthoMab bispecifics platform and high-throughput antibody analytics, we have shown that we can rapidly identify developable T-cell engagers that balance potent cytotoxicity and low cytokine release.”\n\nCD3 T-cell engagers are bispecific antibodies that redirect T cells to kill tumor cells. Developing effective T-cell engagers requires two parental antibodies: a CD3-binding arm that fine-tunes T-cell activation and a tumor-binding arm with high specificity for cancer cells. Pairs of parental antibodies that work well together are rare, creating a need for diverse panels of developable antibodies that can be combined and tested at scale to find optimal clinical candidates.\n\nTo address the paucity of anti-CD3 antibodies for TCEs, AbCellera used its integrated antibody discovery, characterization, and engineering technologies to discover and validate an extensive panel of fully human CD3-binding antibodies. New data presented at SITC includes epitope binning analysis, revealing antibodies with species cross-reactivity that bind epitopes distinct from commonly used parental antibodies, such as SP34-2. AbCellera also conducted a second discovery campaign strategically designed to enhance the number of cross-reactive antibodies in the...